A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

TitleA randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.
Publication TypeJournal Article
Year of Publication2009
AuthorsGandhi RT, O'Neill D, Bosch RJ, Chan ES, R Bucy P, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM
Corporate AuthorsAIDS Clinical Trials Group A5130 team
JournalVaccine
Volume27
Issue43
Pagination6088-94
Date Published2009 Oct 9
ISSN1873-2518
KeywordsAdult, AIDS Vaccines, Anti-Retroviral Agents, Canarypox virus, CD4 Lymphocyte Count, Cell Proliferation, Dendritic Cells, Female, HIV Antibodies, HIV Infections, HIV-1, Humans, Male, Middle Aged, Viral Load
Abstract

Targeting canarypox (CP)-HIV vaccine to dendritic cells (DCs) elicits anti-HIV-1 immune responses in vitro. We conducted a phase I/II clinical trial to evaluate whether adding DC to a CP-HIV vaccine improved virologic control during analytic treatment interruption (ATI) in HIV-1-infected subjects. Twenty-nine subjects on suppressive antiretroviral therapy were randomized to vaccination with autologous DCs infected with CP-HIV+keyhole limpet hemocyanin (KLH) (arm A, n=14) or CP-HIV+KLH alone (arm B, n=15). The mean viral load (VL) setpoint during ATI did not differ between subjects in arms A and B. A higher percentage of subjects in the DC group had a VL setpoint < 5,000 c/mL during ATI (4/13 or 31% in arm A compared with 0/13 in arm B, p=0.096), but virologic control was transient. Subjects in arm A had a greater increase in KLH lymphoproliferative response than subjects in arm B; however, summed ELISPOT responses to HIV-1 antigens did not differ by treatment arm. We conclude that a DC-CP-HIV vaccine is well-tolerated in HIV-1-infected patients, but does not lower VL setpoint during ATI compared with CP-HIV alone. New methods to enhance the immunogenicity and antiviral efficacy of DC-based vaccines for HIV-1 infection are needed.

DOI10.1016/j.vaccine.2009.05.016
Alternate JournalVaccine
PubMed ID19450647
PubMed Central IDPMC2820102
Grant ListA146370 / / PHS HHS / United States
AI066992-04 / AI / NIAID NIH HHS / United States
AI38855 / AI / NIAID NIH HHS / United States
AI38858 / AI / NIAID NIH HHS / United States
AI68634 / AI / NIAID NIH HHS / United States
AI68636 / AI / NIAID NIH HHS / United States
AIO69472 / / PHS HHS / United States
R01 AI066992 / AI / NIAID NIH HHS / United States
R01 AI066992-04 / AI / NIAID NIH HHS / United States
R37 AI044628 / AI / NIAID NIH HHS / United States
R37 AI044628-08 / AI / NIAID NIH HHS / United States
U01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068634-01 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI068636-01 / AI / NIAID NIH HHS / United States
U01 AI069472 / AI / NIAID NIH HHS / United States
U01 AI069472-01 / AI / NIAID NIH HHS / United States